Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Abbassia, Cairo P.O. Box 11381, Egypt.
Clinical Pathology, Medical Ain Shams Research Institute, Ain Shams University, Abbassia, Cairo P.O. Box 11381, Egypt.
Biomolecules. 2022 Sep 2;12(9):1230. doi: 10.3390/biom12091230.
Type 2 Diabetes Mellitus (T2DM) is a metabolic disease associated with inflammation widening the scope of immune-metabolism, linking the inflammation to insulin resistance and beta cell dysfunction. New potential and prognostic biomarkers are urgently required to identify individuals at high risk of β-cell dysfunction and pre-DM. The DNA-sensing stimulator of interferon genes (STING) is an important component of innate immune signaling that governs inflammation-mediated T2DM. NOD-like receptor (NLR) reduces STING-dependent innate immune activation in response to cyclic di-GMP and DNA viruses by impeding STING-TBK1 interaction. We proposed exploring novel blood-based mRNA signatures that are selective for components related to inflammatory, immune, and metabolic stress which may reveal the landscape of T2DM progression for diagnosing or treating patients in the pre-DM state. In this study, we used microarray data set to identify a group of differentially expressed mRNAs related to the cGAS/STING, NODlike receptor pathways (NLR) and T2DM. Then, we comparatively analyzed six mRNAs expression levels in healthy individuals, prediabetes (pre-DM) and T2DM patients by real-time PCR. The expressions of ZBP1, DDX58, NFKB1 and CHUK were significantly higher in the pre-DM group compared to either healthy control or T2DM patients. The expression of ZBP1 and NFKB1 mRNA could discriminate between good versus poor glycemic control groups. HSPA1B mRNA showed a significant difference in its expression regarding the insulin resistance. Linear regression analysis revealed that LDLc, HSPA1B and NFKB1 were significant variables for the prediction of pre-DM from the healthy control. Our study shed light on a new finding that addresses the role of ZBP1 and HSPA1B in the early prediction and progression of T2DM.
2 型糖尿病(T2DM)是一种与炎症相关的代谢疾病,扩大了免疫代谢的范围,将炎症与胰岛素抵抗和β细胞功能障碍联系起来。迫切需要新的潜在和预后生物标志物来识别β细胞功能障碍和糖尿病前期(pre-DM)高危个体。干扰素基因刺激物(STING)是先天免疫信号的重要组成部分,可调节炎症介导的 T2DM。核苷酸结合寡聚化结构域样受体(NLR)通过阻碍 STING-TBK1 相互作用,减少 STING 依赖性先天免疫激活对环二鸟苷酸和 DNA 病毒的反应。我们提出探索新型基于血液的 mRNA 特征,这些特征对与炎症、免疫和代谢应激相关的成分具有选择性,这可能揭示 T2DM 进展的全貌,用于诊断或治疗 pre-DM 状态的患者。在这项研究中,我们使用微阵列数据集来鉴定一组与 cGAS/STING、NOD 样受体途径(NLR)和 T2DM 相关的差异表达的 mRNAs。然后,我们通过实时 PCR 比较分析了健康个体、pre-DM 和 T2DM 患者中 6 种 mRNA 的表达水平。ZBP1、DDX58、NFKB1 和 CHUK 在 pre-DM 组中的表达明显高于健康对照组或 T2DM 患者。ZBP1 和 NFKB1 mRNA 的表达可区分血糖控制良好与不良的患者。HSPA1B mRNA 的表达在胰岛素抵抗方面存在显著差异。线性回归分析显示,LDLc、HSPA1B 和 NFKB1 是从健康对照组预测 pre-DM 的显著变量。我们的研究揭示了一个新的发现,即 ZBP1 和 HSPA1B 在 T2DM 的早期预测和进展中的作用。